HPE Managing CINV pocket guide 2019 | Page 72

TABLE 1
(Continuation)
Aprepitant, fosaprepitant,
netupitant CYP3A4 substrates (dexamethasone,
midazolam, chemotherapy agents)
Aprepitant, fosaprepitant CYP2C9 substrates
Oral contraceptives
Rolapitant CYP2D6 substrates. Breast cancer
resistance protein (BCRP) substrates
P-gp substrates
Olanzapine (use in CINV is off-
label) Strong CYP1A2 inhibitors
Strong CYP1A2 inducers
Olanzapine (use in CINV is off-
label Dexamethasone
Activated charcoal, antacids
Pharmacodynamic interactions
First-generation 5-HT 3 RA,
olanzapine QTc prolonging drugs
5-HT 3 RA Antidepressants
Tramadol
72 | 2019 | hospitalpharmacyeurope.com